NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Recruitment Status: Enrolling by invitation

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Sponsor

Poseida Therapeutics, Inc.

Collaborator

California Institute for Regenerative Medicine (CIRM)

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT03741127

Official Title: Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

First Posted: November 14, 2018

Click here for details on Clinicaltrials.gov

---

CART - BCMA : National Cancer Institute

Biological: P-BCMA-101 CAR-T cells

Drug: Rimiducid

---

Biological: P-BCMA-101 CAR-T cells

autologous anti-BCMA centyrin-based chimeric antigen receptor-expressing Tscm

autologous P-BCMA-101 CAR-T cells

autologous P-BCMA-101 CARTyrin-T cells

Drug: Rimiducid

Drug: Rimiducid may be administered as indicated

---

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Illinois

United States, Kansas

United States, Maryland

United States, Michigan

United States, New Jersey

United States, Pennsylvania

United States, Tennessee

United States, Texas